Photo from wikipedia
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples in a Phase I study of mirvetuximab soravtansine, a FRα-targeting antibody drug conjugate (ADC), in relapsed epithelial… Click to show full abstract
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples in a Phase I study of mirvetuximab soravtansine, a FRα-targeting antibody drug conjugate (ADC), in relapsed epithelial ovarian cancer patients Lainie P. Martin1, Jason A. Konner2, Kathleen N. Moore3, Shelly M. Seward4, Ursula A. Matulonis5, Raymond P. Perez6, Marian Themeles7, Joseph Ponte7, Jianhua Zhao7, Rodrigo Ruiz-Soto7, Michael J. Birrer8 1Fox Chase Cancer Center, Philadelphia, PA; 2Memorial Sloan Kettering Cancer Center, New York, NY; 3University of Oklahoma Health Sciences Center, Oklahoma City, OK; 5Wayne State University – Karmanos Cancer Institute, Huntington Woods, MI; 5Dana Farber Cancer Institute, Boston, MA; 6University of Kansas, Fairway, KS; 7ImmunoGen, Inc., Waltham, MA; 8Massachusetts General Hospital, Boston, MA.
Journal Title: Gynecologic Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!